Trial · NCT03567473
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Admission to hospital for bronchiolitis within 7 days post enrollment | 7 days post enrollment | 1\) patient being admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater. |
| Secondary | Admission to hospital for bronchiolitis at the time of the enrollment ED visit | Enrollment visit | 1\) patient being admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater. |
| Secondary | All cause admission to Hospital within 21 days following enrollment ED visit | up to 21 days post enrollment | 1\) patient being admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater. |
| Secondary | All cause Health care provider visits (including ED visits) by day 21 following enrollment ED | up to 21 days post enrollment | Visits to ED, other clinic, primary care provider, or any visit to see a nurse or physician following enrollment |
| Secondary | Health Care related costs within the 21 days following enrollment ED visits. | up to 21 days post enrollment | Health care related costs |
| Other | Safety outcome 1: Gastrointestinal bleeding | up to 21 days post enrollment | involving melena or frank blood per rectum (and not attributable to other causes, as determined by the treating physician) |
| Other | Safety outcome 2: Serious Bacterial Infection | up to 21 days post enrollment | meningitis, osteomyelitis or septicaemia |
| Other | Safety outcome 3: Severe Varicella | up to 21 days post enrollment | All of the following including: arthritis, osteomyelitis, symptomatic hepatitis, pancreatitis, cerebritis, pneumonitis, glomerulonephritis, disseminated intravascular coagulation, thrombo-cytopenia, prolonged vesicular rash (\<3 weeks), fasciitis, septicaemia, ocular complications, orchitis, myocarditis, intensive care admission and death |
| Other | Safety outcome 4: Death | up to 21 days post enrollment | Death |
| Other | Exploratory Outcome 1: Admission to hospital for bronchiolitis within 21 days following enrollment ED visit | up to 21 days post enrollment | 1\) Patient admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater. |
| Other | Exploratory Outcome 2: Admission to ICU within 21 days following enrollment ED visit for bronchiolitis and requiring intubation or continuous positive airway pressure (CPAP) | up to 21 days post enrollment | Physician admitting patient to ICU for bronchiolitis and requiring oxygen or ventilatory support |
| Other | Exploratory Outcome 3: All cause admission to hospital with 7 days following enrollment ED visit | up to 7 days post enrollment ED visit | 1\) Patient admitted to inpatient ward, or 2) an ED length of stay 12 hours or greater or 3) a combined ED and observation unit stay of 12 hours or greater. |
| Other | Exploratory Outcome 4: All cause ED visits within 21 days following enrollment ED visit | up to 21 days post enrollment ED | Visits to the ED after initial enrollment ED visit |
| Other | Exploratory Outcome 5: Length of stay for the enrollment ED visit (in hours) | Enrollment ED visit | defined as discharge time minus oral study medication time, for participants discharged at the enrollment ED |
| Other | Exploratory Outcome 6: Length of hospital admission for those patients admitted at their enrollment visit | Admissions at enrollment ED visit | time of hospital discharge minus the time of oral study medication |
| Other | Exploratory Outcome 7: Resolution of symptoms as documented on a standardized questionnaire during the telephone or email at day 7 and 21 days. | up to 21 days post enrollment | cough, noisy breathing, respiratory distress, sleep and ability to feed |
| Other | Exploratory Outcome 8: Out of pocket expenses | up to 21 days post enrollment | transportation, days of missed work, missed leisure activities |
| Other | Exploratory Outcome 10: Health care utilization (including ambulatory visits, ED visits, hospitalization) for respiratory illness | Up to 18 years of age | future health care utilization |
| Other | Exploratory Outcome 11: Development of respiratory illnesses | Up to 18 years of age | asthma, wheezing and other respiratory illnesses |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03567473/registered